Advancing CAR-T Cell Therapy: Biomarker Discovery and Toxicity Management in Pediatric and Young-Adult Populations
CAR-T cell therapy has substantially improved treatment options for relapsed or refractory hematologic malignancies, but clinically important toxicities remain, particularly cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and treatment-related cytopenias. This article pr...